Ethics In Spotlight As Scientists Jumpstart Precision Medicine In China
This article was originally published in PharmAsia News
Researchers like Harvard professor Sunny Xiaoliang Xie, who is spearheading the development of China’s first domestic genome sequencer, are carefully navigating tricky terrain while leading the charge to reduce the country’s huge birth deficiency burden and tackle next-generation cancer therapies.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.